Your browser doesn't support javascript.
loading
Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy.
Barbour, Sean J; Coppo, Rosanna; Zhang, Hong; Liu, Zhi-Hong; Suzuki, Yusuke; Matsuzaki, Keiichi; Er, Lee; Reich, Heather N; Barratt, Jonathan; Cattran, Daniel C.
Afiliação
  • Barbour SJ; Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada; BC Renal, Vancouver, British Columbia, Canada. Electronic address: sean.barbour@vch.ca.
  • Coppo R; Fondazione Ricerca Molinette, Regina Margherita Hospital, Turin, Italy.
  • Zhang H; Peking University Institute of Nephrology, Beijing, China.
  • Liu ZH; Nanjing University School of Medicine, Nanjing, China.
  • Suzuki Y; Faculty of Medicine, Juntendo University, Tokyo, Japan.
  • Matsuzaki K; Faculty of Medicine, Juntendo University, Tokyo, Japan.
  • Er L; BC Renal, Vancouver, British Columbia, Canada.
  • Reich HN; Division of Nephrology, University of Toronto, Toronto, Ontario, Canada.
  • Barratt J; Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
  • Cattran DC; Division of Nephrology, University of Toronto, Toronto, Ontario, Canada. Electronic address: daniel.cattran@uhn.ca.
Kidney Int ; 102(1): 160-172, 2022 07.
Article em En | MEDLINE | ID: mdl-35490842
The International IgA Nephropathy (IgAN) Prediction Tool is the preferred method in the 2021 KDIGO guidelines to predict, at the time of kidney biopsy, the risk of a 50% drop in estimated glomerular filtration rate or kidney failure. However, it is not known if the Prediction Tool can be accurately applied after a period of observation post-biopsy. Using an international multi-ethnic derivation cohort of 2,507 adults with IgAN, we updated the Prediction Tool for use one year after biopsy, and externally validated this in a cohort of 722 adults. The original Prediction Tool applied at one-year without modification had a coefficient of variation (R2) of 55% and 54% and four-year concordance (C statistic) of 0.82 but poor calibration with under-prediction of risk (integrated calibration index (ICI) 1.54 and 2.11, with and without race, respectively). Our updated Prediction Tool had a better model fit with higher R2 (61% and 60%), significant increase in four-year C-statistic (0.87 and 0.86) and better four-year calibration with lower ICI (0.75 and 0.35). On external validation, the updated Prediction Tool had similar R2 (60% and 58%) and four-year C-statistics (both 0.85) compared to the derivation analysis, with excellent four-year calibration (ICI 0.62 and 0.56). This updated Prediction Tool had similar prediction performance when used two years after biopsy. Thus, the original Prediction Tool should be used only at the time of biopsy whereas our updated Prediction Tool can be used for risk stratification one or two years post-biopsy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Insuficiência Renal / Glomerulonefrite por IGA Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Revista: Kidney Int Ano de publicação: 2022 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Insuficiência Renal / Glomerulonefrite por IGA Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Revista: Kidney Int Ano de publicação: 2022 Tipo de documento: Article País de publicação: Estados Unidos